Alternative cross-priming through CCL17-CCR4-mediated attraction of CTLs toward NKT cell–licensed DCs

Dendritic cells classically require cognate licensing by helper T cells to cross-prime cytotoxic T cells. Kurts and colleagues have found an alternative mechanism of cognate licensing mediated by natural killer T cells. Cross-priming allows dendritic cells (DCs) to induce cytotoxic T cell (CTL) resp...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature immunology 2010-04, Vol.11 (4), p.313-320
Hauptverfasser: Semmling, Verena, Lukacs-Kornek, Veronika, Thaiss, Christoph A, Quast, Thomas, Hochheiser, Katharina, Panzer, Ulf, Rossjohn, Jamie, Perlmutter, Patrick, Cao, Jia, Godfrey, Dale I, Savage, Paul B, Knolle, Percy A, Kolanus, Waldemar, Förster, Irmgard, Kurts, Christian
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Dendritic cells classically require cognate licensing by helper T cells to cross-prime cytotoxic T cells. Kurts and colleagues have found an alternative mechanism of cognate licensing mediated by natural killer T cells. Cross-priming allows dendritic cells (DCs) to induce cytotoxic T cell (CTL) responses to extracellular antigens. DCs require cognate 'licensing' for cross-priming, classically by helper T cells. Here we demonstrate an alternative mechanism for cognate licensing by natural killer T (NKT) cells recognizing microbial or synthetic glycolipid antigens. Such licensing caused cross-priming CD8α + DCs to produce the chemokine CCL17, which attracted naive CTLs expressing the chemokine receptor CCR4. In contrast, DCs licensed by helper T cells recruited CTLs using CCR5 ligands. Thus, depending on the type of antigen they encounter, DCs can be licensed for cross-priming by NKT cells or helper T cells and use at least two independent chemokine pathways to attract naive CTLs. Because these chemokines acted synergistically, this can potentially be exploited to improve vaccinations.
ISSN:1529-2908
1529-2916
DOI:10.1038/ni.1848